

EXHIBIT 1

EXHIBIT 2

Sep-21-06 02:06pm From:ADA (GDT PROCTER LLP

16172278581

T-718 P 01/05 F-510

GOODWIN | PROCTERGoodwin Procter LLP
Counsellors at Law
Exchange Place
Boston, MA 02109
T: 617.570.1000**F A X T R A N S M I T T A L**

If problems with transmittal, call fax department at 617 570 1498

Date	Total pages	Attorney number	Client/matter number
September 21, 2006			

To	Company	Fax number	Telephone
Matthew P. Hendrickson		212-504-6666	
Chad J. Peterman		212-504-6666	
Brndley J. Demuth		212-504-6666	
Josy W. Ingersoll		302-576-3301	
Frederick L. Conrell, III		302-651-7701	
Mary B. Graham		302-658-3989	
Mary Mannerer		302-571-1750	
Jeffrey S. Gouless		302-658-7567	
Pamela S. Tikellis		302-656-9053	
Elizabeth M. McGeever		302-658-8111	
Steven C. Sunshine		202-862-2400	
Timothy Bickham		202-429-3902	
Bruce Gagala		312-616-5700	
Timothy Bickman		202-429-3902	
Asim Bhansali		415-397-7188	
Barry S. Taus		212-764-6620	

The information contained in this communication is intended only for the personal and confidential use of the designated recipients addressed. This message may be an attorney-client communication from an attorney at the law firm of Goodwin Procter LLP and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this communication in error and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error please notify us at the telephone number shown above, and return the original message to us by mail. Thank you.

Sep-21--06 02:06pm From:ADA (GDT PROCTER LLP

16172278501

T-718 P 02/05 F-510

Adam Steinfeld	212-764-6620	
Scott Perwin	305-372-1861	
Joseph T. Lukens	215-568-0300	
David Nalven	617-482-3003	
Christopher McDonald	212-883-7061	
John Turner	214-754-1933	
Bernard Persky	212-818-0477	
Brian Clobes	215-864-2810	
Ted Lieberman	215-496-6611	
Jeff Kodroff	215-496-6611	
<hr/>		
From	Fax number	Telephone
Christopher T. Holding	617-523-1231	617-570-1679

LIBA/16821591

The information contained in this communication is intended only for the personal and confidential use of the designated recipients addressed. This message may be an attorney-client communication from an attorney at the law firm of Godwin Procter LLP and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this communication in error and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify us at the telephone number shown above and return the original message to us by mail. Thank you.

Sep-21-06 02:07pm From:ADA (GDT PROCTER LLP

16172278581

T-718 P 03/05 F-510

GOODWIN | PROCTER

Christopher T. Holding
617 570 1679
cholding@
goodwinprocter.com

Goodwin Procter LLP
Counselors at Law
Exchange Place
Boston, MA 02109
T 617 570 1000
F 617 523 1231

September 21, 2006

By Facsimile and First Class Mail

Matthew P. Hendrickson, Esq.
Cadwalader, Wickersham & Taft LLP
One World Financial Center
New York, NY 10281

**Re: Abbott Laboratories, et al. v. Teva Pharmaceuticals USA, Inc.
C.A. No. 02-1512 (KAJ) (consolidated)**

Dear Matt :

I write in response to your letter of September 19, 2006 concerning the deposition of Pascale Blouquin. I understand that Ms. Blouquin is still employed by Fournier. As a current-employee, we believe that a further deposition of Ms. Blouquin as part of the anti-trust case is appropriate and that no explanation or description of topics is required. In order to resolve this dispute, however, we are willing to provide the following explanation.

First, let me be clear that it has never been our intention to re-cover ground about which Ms. Blouquin has already been questioned.

Second, while there is some overlap between the issues in the patent case and the antitrust issues, there are additional questions now in dispute between the parties. This includes questions that have arisen since the patent case (such as the participation of Ms. Blouquin in the continued prosecution of related patent applications and the submission of materials from the patent litigation to the Patent and Trademark Office); the further identification of Ms. Blouquin on privileged documents; and the involvement of Ms. Blouquin in both meetings between Abbott and Fournier concerning fenofibrate products and the development of the replacement fenofibrate formulation. There are, furthermore, other issues on which Ms. Blouquin was not fully questioned during her initial deposition, given the priorities of the case at that time and limited time for which Ms. Blouquin was provided for deposition. These include, among other things, the involvement of Ms. Blouquin in the prosecution of any of the patents in suit,

cc: Chad J. Peterman
Bradley J. Demuth
Josy W. Ingersoll
Frederick L. Cottrell, III
Mary B. Graham
Mary Matterer
Jeffrey S. Goddess
Pamela S. Tikellis
Elizabeth M. McGeever
Steven C. Sunshine
Timothy Bickham
Bruce Gagala
Timothy Bickman
Asim Bhansali
Barry S. Taus
Adam Steinfeld
Scott Perwin
Joseph T. Lukens
David Nalven
Christopher McDonald

Sep-21-06 02:07pm From:ADA (GDT PROCTER LLP

16172278581

T-718 P 05/05 F-510

GOODWIN | PROCTER

Matthew R. Hendrickson, Esq.
September 21, 2006
Page 3

John Turner
Bernard Persky
Brian Clobes
Ted Lieberman
Jeff Kodroff

EXHIBIT 3

C A D W A L A D E R

Cadwalader Wickersham & Taft LLP
New York London Charlotte Washington Beijing

One World Financial Center, New York, NY 10281
Tel 212 504 6000 Fax 212 504 6666
www.cadwalader.com

October 2, 2006

VIA FACSIMILE +1 (617) 523-1231

Christopher T. Holding, Esq.
Goodwin Procter LLP
Exchange Place
53 State Street
Boston, MA 02109-2881

Re: Abbott Laboratories v. Teva Pharmaceuticals USA, Inc., C.A. 02-1512 (K.A.)
(D. Del.) (consolidated).

Dear Chris:

Thank you for your letter of September 21

While you acknowledge in your letter the impropriety of re-covering prior depositions, your proposed re-deposition topics for the "antitrust phase" of this litigation contemplate yet another examination of Ms. Blouquin on what can only be characterized as the same topics for which she was made available for deposition in connection with the patent litigations. As explained below, we simply cannot agree to make Ms. Blouquin available for such a duplicative and burdensome deposition.

Ms. Blouquin is a scientist. She has already testified repeatedly about the areas on which she has any knowledge relating to TriCor, which are limited to the scientific issues in the patent litigations. There is no allegation — nor could there be — that Ms. Blouquin had any involvement in any of the marketing or other alleged conduct that are the only new allegations in the "antitrust phase" of this case. The relevance of Ms. Blouquin to the antitrust claims arises from her role in the exact issues that were contested and thoroughly explored by Teva and Impax in the "patent phase" of this litigation. The facts she possesses are the same, whether relevant to a patent infringement defense or an alleged antitrust violation.

Teva and the other antitrust Plaintiffs allege that the patent suits were sham litigations that gave rise to antitrust liability because Fournier and Abbott knew the patents-in-suit were invalid and unenforceable. More specifically to Ms. Blouquin, Plaintiffs allege that she

C A D W A L L A D E R

Christopher T. Holding, Esq.
October 2, 2006

See, e.g., Teva's Second Amended Counterclaims ¶¶ 118, 123, 159-160, 223

Teva and Impax already conducted extensive discovery on these issues, and twice deposed Ms. Blouquin in the patent litigations.¹ Among other topics, Ms. Blouquin testified about the and the other similar documents, which Teva used as deposition exhibits Plaintiffs' antitrust claims, as they relate to the areas about which Ms. Blouquin could testify. simply mirror the issues Teva and Impax have previously raised and explored in the patent litigations

That any further deposition of Ms. Blouquin in this case would be unreasonably duplicative and unduly burdensome is confirmed by review of your proposed re-deposition topics.

First, you indicate that you would like to depose Ms. Blouquin about her participation in the prosecution of certain patent applications that were filed after the patent cases. All of the patents at issue in this case were issued before Ms. Blouquin's last deposition, and Plaintiffs had every opportunity to question her on those patent applications.

Second, you propose questioning Ms. Blouquin about unidentified "privileged documents." We would not waive any privilege, and thus believe there are better, more cost-efficient means to obtain whatever non-privileged information you may be after other than by further deposing Ms. Blouquin. Moreover, to the extent any of these unidentified documents were produced in the patent cases, you have not provided any reason for why Teva and Impax were not able to question her on these documents during her previous depositions.

You also indicate that you want to question Ms. Blouquin about her involvement in "meetings between Abbott and Fournier" and the development of the "replacement fenofibrate formulation." Plaintiffs have already scheduled depositions of the key Abbott and Fournier participants in these meetings, and have not explained how also deposing Ms. Blouquin would not be duplicative on the issues. Moreover, given that Ms. Blouquin was last deposed in June 2004 and the NFE TriCor formulation was introduced in November 2004, her testimony about fenofibrate research conducted subsequent to her deposition would largely be on the development of products not at issue in this litigation and that are covered by the Court's ruling on future business products.

¹ In addition to twice deposing Ms. Blouquin in her individual capacity, Teva and Impax also deposed Ms. Blouquin in her capacity as Fournier's 30(b)(6) designee concerning Fournier's acquisition of Pharma Pass technology and its development of the 160 mg tablet TriCor formulation.

C A D W A L A D E R

Christopher T. Holding, Esq.
October 2, 2006

Lastly, as noted above, you propose questioning Ms. Blouquin on issues that could have been, but were not, raised during her prior depositions because you claim that Teva was "not able [to] fully question[]" Ms. Blouquin because of the "limited time for which Ms. Blouquin was provided for deposition." Your suggestion that her prior depositions were somehow limited and therefore inadequate is at odds with the facts. In addition to the 2001 deposition of Ms. Blouquin by Impax, the 2004 deposition of Ms. Blouquin by Teva and Impax in this case spanned two days. Neither Teva nor Impax suggested at the time that this deposition of Ms. Blouquin was in any way deficient, and these were issues on which Teva was ready for trial.

Finally, we do not believe you have given sufficient weight to the burden on the witness. In an effort to be accommodating, we agreed to make Ms. Blouquin available in Paris on October 13 if we are required to produce her, but she lives in Dijon and would need to travel to Paris for her deposition. The stress and burden of a U.S.-style deposition for a foreign witness not accustomed with the U.S. system is considerable, even for someone who has already been subject to multiple depositions.

In sum, we do not agree that your proposed re-deposition topics and explanation justify the need for a third deposition of Ms. Blouquin by the Plaintiffs and we cannot agree to your request.

Very truly yours,



Matthew P. Hendrickson

cc: S. Jason Baletsa, Esq.
Anne S. Gaza, Esq.
Chad J. Peterman, Esq.
Mary B. Graham, Esq.
Josy W. Ingersoll, Esq.
Mary Matterer, Esq.
Jeffery S. Goddess, Esq.
Pamela S. Tikellis, Esq.
Elizabeth M. McGeever, Esq.
Bruce Gagala, Esq.
Asim Bhansali, Esq.

C A D W A L L A D E R

Christopher T Holding, Esq.
October 2, 2006

Barry Taus, Esq
Adam Steinfeld, Esq.
Scott E Perwin, Esq
Joseph T Lukens, Esq
David Nalven, Esq
Christopher McDonald, Esq.
John W Turner, Esq
Bernard Persky, Esq
Brian L Clobes, Esq.
Ted Lieberman, Esq
Jeffrey L Kodroft, Esq

**EXHIBITS 4-8
REDACTED**

EXHIBIT 9

CADWALADER

Cadwalader, Wickersham & Taft LLP
New York London Charlotte Washington Beijing

One World Financial Center, New York, NY 10281
Tel 212 504 6000 Fax 212 504 6666
www.cadwalader.com

September 14, 2006

VIA E-MAIL

Asim Bhansali, Esq.
Keker & Van Nest, L.L.P.
710 Sansome Street
San Francisco, CA 94111-1704

Re: *Abbott Laboratories v. Impax Laboratories, Inc.*, C.A. No. 03-120 (K.A.J.) (D. Del.) (consolidated)

Dear Asim:

We are in receipt of the documents Impax Laboratories, Inc. ("Impax") produced on CDs numbered Impax 001 through Impax 009 apparently in response to Defendants' first and second set of requests for production of documents and things, and have identified several issues with Impax's document production to date.

Notwithstanding that Impax produced well over 650,000 pages — substantially more than any other Plaintiff in this litigation, it appears that Impax failed to produce numerous categories of documents requested. It also appears that many of the produced pages were redacted substantially, and that Impax otherwise widely redacted responsive, discoverable, non-privileged information from its production. Given the approaching discovery deadline and upcoming Impax depositions, we request, by September 21, that Impax respond to this letter with an explanation and supplemental production that addresses, at the very least, the following deficiencies in Impax's document production to date:

1. No documents relating to sale or purchase of Impax Fenofibrate Products with any wholesaler or retail pharmacy (e.g., Defendants' RFP No. 3).
2. No documents relating to examples of marketing and promotional information detailing materials for Impax Fenofibrate Products (e.g., Defendants' RFP No. 4).
3. Deficient and incomplete production of documents pertaining to strategic plans, manufacturing plans, business plans, launch plans, and market analyses regarding Impax Fenofibrate Products (e.g., Defendants' RFP No. 5).

Bradley J. Demuth Tel 212 504 6503 Fax 212 504 6666 brad.demuth@cwt.com

C A D W A L A D E R

Asim Bhansali, Esq.
September 14, 2006

4. No documents relating to guidelines, procedures, strategies and policies related to selling prices for Impax Fenofibrate Products (*e.g.*, Defendants' RFP No. 6).
5. Incomplete production of documents relating to projections, estimates, or assumptions underlying projections or estimates of sales volume, sales quantity, revenue and profit margins for Impax Fenofibrate Productions (*e.g.*, Defendants' RFP No. 7).
6. Minimal and incomplete documents relating to size and scope of sales force used or intended to be used by Impax or documentation relating to sales force working on behalf of Impax to promote, market, or sell Impax Fenofibrate Products (*e.g.*, Defendants' RFP No. 9).
7. No documents relating to Impax's expenditures or anticipated expenditures, on a month to month basis for marketing and other promotional efforts relating to Impax Fenofibrate Products (*e.g.*, Defendants' RFP No. 10).
8. No documents relating to statements either oral or written made to Congress or any Government Entity concerning the Hatch-Waxman amendments (*e.g.*, Defendants' RFP 12).
9. No documents relating to Impax's communication with First Databank or Medispan with respect to Tricor®, Lofibra®, or any Fenofibrate Product (*e.g.*, Defendants' RFP No. 14).
10. No documents relating to Impax's production of documents to the U.S. Federal Trade Commission in connection with the investigation titled Abbott Laboratories, File 005-0124 (*e.g.*, Defendants' RFP No. 16).
11. Minimal and incomplete documents relating to information or data considered or relied upon by Impax in determining the relevant product market (*e.g.*, Defendants' RFP No. 18).
12. No documents relating to substitutability or non-substitutability of TriCor, Lofibra, any Fenofibrate Products, or any Pharmaceutical Products for human treatment (*e.g.*, Defendants' RFP No. 19).
13. Minimal documents relating to reasons or indications for prescribing Fenofibrate Products or other Pharmaceutical Products to regulate cholesterol levels in humans (*e.g.*, Defendants' RFP No. 20).


C A D W A L A D E R

Asim Bhansali, Esq.
September 14, 2006

14. Minimal documents relating to information and documents identified in Impax's initial disclosures, pursuant to Fed. R. Civ. P. 26(a)(1), specifically, documents regarding the effects of Abbott and Fournier's allegedly blocking Impax's ability to market Fenofibrate Products (*e.g.*, Impax Initial Disclosures No. 5).
15. No documents relating to customer, market, and/or physician preferences regarding the taking of Fenofibrate in capsule versus tablet form (*e.g.*, Defendants' RFP No. 28).
16. No documents relating to advantages or disadvantages of Fenofibrate in tablet form. (*e.g.*, Defendants' RFP No. 29).
17. No documents relating to customer, market, or physician preferences regarding the taking of medication in lower versus higher dosages of active ingredient (*e.g.*, Defendants' RFP No. 30).
18. No documents relating to customer, market, or physician preferences regarding medication that need not be taken with food (*e.g.*, Defendants' RFP No. 31).
19. No documents relating to patient compliance with taking Fenofibrate medication that must be taken with food (*e.g.*, Defendants' RFP No. 32).
20. No documents relating to Triglide™'s effect on potential Impax Fenofibrate Product sales (*e.g.*, Defendants' RFP No. 38).
21. No documents relating to communications regarding Teva's fenofibrate products or any potential Teva Fenofibrate Product, which Teva intended to sell (*e.g.*, Defendant's RFP Nos. 41, 42).

The deficiencies described above are the most significant we have identified so far. We reserve our right to object to any further deficiencies in Impax's document productions. We are happy to discuss these deficiencies within the next week, but, given the impending discovery deadline and Impax depositions, any meet and confer must be followed by prompt action. I am available for a teleconference this week to discuss any issues further.

Sincerely,


Bradley J. Demuth

C A D W A L A D E R

Asim Bhansali, Esq.
September 14, 2006

cc: Paula L. Blizzard, Esq.
R. James Slaughter, Esq.
Anne S. Gaza, Esq.
Chad J. Peterman, Esq.
Mary B. Graham, Esq.

EXHIBIT 10

LAW OFFICES
KEKER & VAN NEST
LLP

710 SANSOME STREET
SAN FRANCISCO, CA 94111-1704
TELEPHONE (415) 391-5400
FAX (415) 397-7188

FACSIMILE TRANSMISSION COVER SHEET

September 27, 2006

To	Telephone	Facsimile
Bradley J. Demuth Cadwalader, Wickersham & Taft LLP	(212) 504-6503	(212) 504-6666
Chad J. Peterman Patterson Belknap Webb & Tyler LLP	(212) 336-2877	(212) 336-7914
Mary B. Graham Morris Nichols Arsht & Tunnell	(302) 658-9200	(302) 658-3989
Anne Shea Gaza Richards Layton & Finger, P.A.	(302) 651-7539	(302) 498-7539

From	Telephone	Code
R. James Slaughter	(415) 773-6608	6171/gap
Re <i>Abbott Laboratories, et al. v. Impax, Inc.</i> USDC, Dist. of Delaware, Case No. 03-120-KAJ		

Number of Pages (Including Cover): 2

NO ORIGINAL WILL FOLLOW THIS TRANSMISSION

COMMENTS

Please see attached.

Operator _____

Time Sent _____

IF YOU ENCOUNTER ANY DIFFICULTIES RECEIVING THIS TRANSMISSION,
PLEASE CALL (415) 676-2277 OR (415) 391-5400

The information contained in this facsimile transmission is legally privileged and confidential and intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify us immediately by telephone, and return the original transmission to us at the above address via the U.S. Postal Service. Thank you.

LAW OFFICES
KEKER & VAN NEST
LLP

710 SANSOME STREET
SAN FRANCISCO, CA 94111-1704
TELEPHONE (415) 391-5400
FAX (415) 397-7188
WWW.KVN.COM

R. JAMES SLAUGHTER
RSLAUGHTER@KVN.COM

September 27, 2006

VIA FACSIMILE

Bradley J. Demuth
Cadwalader, Wickersham & Taft LLP
One World Financial Center
New York, NY 10281


Re: *Abbott Laboratories v. Impax, Inc.*
C.A. No. 03-120 KAJ (consolidated)

Dear Brad:

I write in response to your letter of September 14, 2006, regarding Impax's document production.

As you note in your letter, Impax has produced a substantial number of documents—more than 650,000 pages. These documents were not chosen at random, but rather were collected and produced in the course of a careful set of searches for documents in response to your various, broad requests and subject to objections made to those requests. Our searches in response to your first document request were reasonably designed to capture all responsive documents not previously produced. In response to your second request, we attempted to capture any documents that would not have been captured by our first search. (We did not re-run the searches on matters that would have been duplicative of our first collection effort.) We will be making an additional production by the end of this week or early next. Quite simply, Impax has made reasonable, good faith efforts to collect and produce all documents responsive to your requests. The fact that you have not found documents you believe might exist does not mean that we did not search for them. And to the extent that you have a concern regarding the (large) size of our production, that is the result of the broad request you served.

Very truly yours,


R. JAMES SLAUGHTER

RJS/mls

cc: Anne S. Gaza, Esq. (via facsimile)
Chad J. Peterman, Esq. (via facsimile)
Mary B. Graham, Esq. (via facsimile)

EXHIBIT 11

CADWALADER

Cadwalader, Wickersham & Taft LLP
New York London Charlotte Washington Beijing

One World Financial Center, New York, NY 10281
Tel 212 504 6000 Fax 212 504 6666
www.cadwalader.com

September 29, 2006

VIA E-MAIL

Asim Bhansali, Esq
Keker & Van Nest, L L P
710 Sansome Street
San Francisco, CA 94111-1704

Re: Abbott Laboratories v Impax Laboratories Inc., C.A. No. 03-120 (KAI) (D. Del.) (consolidated)

Dear Asim:

I write in response to your letter of September 11 and to follow up on James Slaughter's letter of September 27.

In your September 11 letter, you indicate that Impax inadvertently produced approximately 194,000 pages of documents without intended redactions, and request that we (i) accept two replacement CDs, IMPAX 005 and IMPAX 009, containing corrected copies of all these documents, (ii) return the original CDs, and (iii) destroy all corresponding hard copies of these documents. The replacement CDs are full of documents that are either significantly or wholly redacted of substance. Nowhere in your letter do you indicate the basis for these redactions or even whether any of the replaced documents concern privileged information. As a result, we cannot agree to your request.

These redactions are indicative of a broader concern about Impax's entire production to date. As noted in my September 14 letter, Impax's production suffers from a number of deficiencies, including that it is rife with extensive and unexplained redactions. Take for example, IMPAX 516085, but has been considerably redacted without explanation. Other iterations of this document (see, e.g., IMPAX 278609 and IMPAX 521671) demonstrate that Impax redacted plainly relevant, responsive, and discoverable information. Other examples include: (i) IMPAX 014612-29, , that has been completely redacted of substance, including from seemingly relevant and responsive pages entitled ; (ii) IMPAX 157599-600, which by its subject line should have been produced unredacted, and which has been redacted so extensively that understanding the document is impossible; and (iii) numerous copies and iterations of voluminous spreadsheets with nearly every page redacted. Impax's documents are so heavily redacted that we cannot

¹ In addition, the unredacted information in this document is completely illegible.
Bradley J. Demuth Tel 212 504 6503 Fax 212 504 6666 brad.demuth@cw.com

C A D W A L A D E R


Asim Bhansali, Esq
September 29, 2006

discern the context of the remaining text or even to which of our document requests they respond

James Slaughter's letter of September 27 states that Impax's production of more than 650,000 pages "is the result of the broad request [Defendants] served." Mr. Slaughter also suggests that the volume of the production alone relieves Impax from having to produce any more documents or reveal text redacted from the production made to date. The law makes clear that volume alone does not satisfy a party's discovery obligations under the Federal Rules. As discussed above, Impax's redactions are so extensive, it is as if Impax made no production at all.

I understand that Impax intends to provide a supplemental production shortly. Please confirm by close of business today whether this supplemental production redresses the production deficiencies noted in my letter of September 14, and otherwise consists of unredacted copies of previously produced documents that were — as illustrated by the examples above — redacted without any legitimate basis. It is crucial for Impax to cure its deficiencies sufficiently in advance of the Impax depositions to allow time for a meaning preparation. If we do not hear from you, we will add this issue to the agenda for the October 6 conference if the Court is amenable.

Sincerely,



Bradley J. Demuth

cc: R. James Slaughter, Esq
Anne S. Gaza, Esq
Chad J. Peterman, Esq.
Mary B. Graham, Esq

**EXHIBITS 12-16
REDACTED**

EXHIBIT 17

One Logan Square, 27th Floor
Philadelphia, PA 19103-6933
215-568-0300 / facsimile

30 North Third Street, Suite 700
Harrisburg, PA 17101-1701
717-364-1020 / facsimile

20 Brace Road, Suite 201
Cherry Hill, NJ 08034-2634
856-616-2170 / facsimile

www.hangley.com

HANGLEY
ARONCHICK
SEGAL



PUDLIN

Attorneys at Law | A Professional Corporation

Joseph T. Lukens
Direct Dial: 215-496-7032
E-mail: jlukens@hangley.com

September 22, 2006

Via E-Mail and First Class Mail

Bradley DeMuth, Esq.
Cadwalader, Wickersham & Taft LLP
One World Financial Center
New York, NY 10281

Chad J. Peterman, Esq.
Patterson Belknap Webb & Tyler LLP
1133 Avenue of the Americas
New York, NY 10036-6710

**Re: CVS and Rite Aid v. Abbott Laboratories et al., C.A. 05-605-KAJ;
Walgreen's v. Abbott Laboratories et al., C.A. 05-404-KAJ**

Dear Brad and Chad:

I write on behalf of both the CVS and Rite Aid Plaintiffs and the Walgreen Plaintiffs in response to Brad's September 19, 2006 letter concerning Defendants' intention to move to compel with respect to Defendants' Third Set of Requests for Production of Documents and Things. While there has been some minimal correspondence on these issues, Defendants have determined that the parties are at an impasse primarily on the basis that Plaintiffs have objected to the discovery requests.


Defendants' Third Set of Requests seeks documents concerning comparisons, competition or relative market shares among TriCor and "any other lipid regulating drug product," and how the pricing of any other lipid product is or is not affected by the pricing of any other lipid product. As defined in Defendants' requests, "Other Lipid Product" includes 47 different drugs other than TriCor. This request is extremely broad, and given that Plaintiffs believe there is no relevance to the request, the burden of having to conduct such a broad ranging search grossly outweighs any value to undertaking such a search.

Bradley DeMuth, Esq.
Chad J. Peterman, Esq.
September 22, 2006
Page 2

Nonetheless, in an effort to avoid burdening the Court and the parties with another discovery motion, Plaintiffs are willing to conduct a search for any analysis undertaken by our own employees or consultants that may be responsive to the requests. Plaintiffs believe that the burden of searching at least 47 different vendor files to examine every document prepared by a drug manufacturer that may mention TriCor would be an unduly burdensome task. While Plaintiffs believe that any comparative documents responsive to the requests are not relevant, if any such documents are relevant, they would be analyses prepared by Plaintiffs' own employees or consultants, not materials received from other drug manufacturers that may be located in Plaintiffs' files simply because another drug manufacturer sent them to Plaintiffs.

Please let me know as soon as possible whether Defendants will accept the above as responsive to Defendants' Third Set of Requests for Production of Documents.

Sincerely,

A handwritten signature in black ink, appearing to read "J. Lukens", written over the printed name "Joseph T. Lukens".

cc: All Counsel via email

EXHIBIT 18

CADWALADER

Cadwalader Wickersham & Taft LLP
New York London Charlotte Washington Beijing

One World Financial Center New York, NY 10281
Tel 212 504 6000 Fax 212 504 6666
www.cadwalader.com

September 29, 2006

VIA E-MAIL

Joseph T. Lukens, Esq.
Hangley Aronchick Segal & Pudlin
27th Floor
One Logan Square
Philadelphia, PA 19103

Dear Joe:

I write in response to your letter of September 22, and to follow-up our September 27 telephone conversation.

Our document requests call for Direct Purchaser Plaintiffs to produce all documents in their control, whether drafted by them or not. We understand that you are proposing to create different standards for producing: (1) documents that were created by or at the direction of a Direct Purchaser Plaintiff; and (2) documents that were created by a lipid product manufacturer that are maintained in the files of a Direct Purchaser Plaintiff. In our view, both types of documents are directly relevant to the market definition issues in this case and ought to be produced.¹ That said, we believe a reasonable compromise can be achieved that would address your burden concerns and avoid the need for further involvement of the Court on this issue.

I. Direct Purchaser-Created Documents

We appreciate Direct Purchaser Plaintiffs' offer to search for and produce any documents created by an employee or consultant that may be responsive to Defendants' requests for

¹ Contrary to your letter, the history of our requests, correspondence, and meet and confers indicates that the issue is ripe for resolution by the Court. Defendants first requested production of these documents nearly a year ago, re-requested these documents in subsequent document requests, raised this issue in a meet and confer teleconference, and in repeated correspondence. In response, Direct Purchaser Plaintiffs have repeatedly taken the position that all documents relating to products other than fenofibrate were not relevant and therefore would not be produced, even including when, most recently, we provided direct evidence from the files of Direct Purchaser Plaintiff Walgreen that the relevant market at issue in this case includes non-fenofibrate products. Notwithstanding Plaintiffs' repeated contention that the relevant market is strictly limited to fenofibrate products, Defendants are entitled to full discovery on this disputed issue.

C A D W A L A D E R

Joseph T. Lukens, Esq.
September 29, 2006

documents relating to other lipid products. As we discussed, such documents would include those that compare, discuss, and/or mention fenofibrate (TriCor or any other fenofibrate product) in relation to, or in connection with, any non-fenofibrate lipid regulating product.²

II Manufacturer-Created Documents

In your letter and during our call you took the position that our document requests posed an undue burden because of the vast number of other lipid regulating products that compete with TriCor, including the 47 we identified in our document requests. You also told me that the Direct Purchasers maintain files of manufacturer-created documents by manufacturer name, and that these files were typically organized into two types of folders: (1) a general folder for documents that were not product-specific, and (2) product-specific folders identified by each product distributed by that manufacturer. You said that searching for relevant documents in each type of folder for each of the 47 products was too burdensome. You indicated that you would instead consider searching for responsive documents within the product-specific folders for a limited number of lipid products we identify.

Toward that end, please confirm that, in addition to searching for and producing the documents discussed under Section I above, each Direct Purchaser Plaintiff will search for and produce responsive documents in the following product-specific lipid product files: (1) Lipitor, (2) Vytorin, (3) Crestor, (4) Zetia, (5) Pravachol, (6) Mevacor, (7) Zocor, (8) Lipid, and (9) Niaspan. Considering that each of the Direct Purchaser Plaintiffs has produced so comparatively few documents to date, we believe that the limited number of additional files we ask to be searched for responsive documents is reasonable.

² In connection with this offer, I understood from our call that Direct Purchaser Plaintiff Walgreen would at least produce all responsive documents, including those identified by its 30(b)(6) designee, Jill Nailor, and that all other Direct Purchaser Plaintiffs would produce any such similar documents to the extent they exist.


¹ For example, apart from any electronic purchasing and sales data Direct Purchaser Plaintiffs may have produced, Rite-Aid has produced a total of 1,974 pages to date; Walgreen, only 410 pages; CVS 316 pages; Albertson's, 207 pages; Maxi Drug, 105 pages; Hy-Vec, 103 pages; and Safeway 43 pages. By contrast, Defendants have produced hundreds of thousands of pages.

C A D W A L A D E R

Joseph T. Lukens, Esq
September 29, 2006

Given the Court conference scheduled for next week, a prompt reply is respectfully requested

Very truly yours,

A handwritten signature in black ink, appearing to read "Bradley J. Demuth", with a long horizontal flourish extending to the right.

Bradley J. Demuth

cc: All counsel via email

EXHIBIT 19

Message

Page 1 of 6

Demuth, Brad

From: Demuth, Brad
Sent: Tuesday, October 03, 2006 7:14 PM
To: 'Lukens, Joseph T.'
Cc: 'sperwin@kennynachwaller.com'; 'lravkind@kennynachwaller.com'; Hendrickson, Matthew; 'Bickham, Timothy'; 'Peterman, Chad J. (x2877)'; Reinhart, Tara
Subject: RE: Tricor Letter

Joe:

We cannot agree to your proposal. The distinction you appear to be drawing between "active" and "archived" files is unreasonable (and raised for the first time only just now). The allegations in the complaint span several years including years for which Direct Purchaser Plaintiffs apparently maintain only archive files. Direct Purchaser Plaintiffs have requested from Defendants documents going as far back in time, and we have produced documents in response to those requests. While we are sensitive to burden concerns, Direct Purchaser Plaintiffs are obligated to produce the documents we requested, even if some of these documents are maintained in archived files. If you cannot agree to produce these documents, than I believe, unfortunately, we are at an impasse and will need to proceed with the conference we have scheduled for Friday.

Kind regards,
Brad

From: Lukens, Joseph T. [mailto:jtl@hangley.com]
Sent: Tuesday, October 03, 2006 5:41 PM
To: Demuth, Brad
Cc: sperwin@kennynachwaller.com; lravkind@kennynachwaller.com; Hendrickson, Matthew; Bickham, Timothy; Peterman, Chad J. (x2877); Reinhart, Tara
Subject: RE: Tricor Letter

Brad,

The context of our discussion about documents created by direct purchasers, as is clear from my letter, and my recollection of our conversation, was in the context of documents comparing other products with TriCor or fenofibrate. Obviously, you have a different recollection, though I believe it is different than what you recount in your first paragraph, which, as I stated below, was limited to comparative documents referring to a fenofibrate and any other listed product.

Nonetheless, plaintiffs are willing to look in active files, not archived files (which would grossly increase the burden, particularly for products in that class that were launched many years ago). With respect to Walgreen's, I understand that these forms, to the extent they are generated, are generated upon product launches, and therefore for some of the products listed, to the extent such a form was created, it may be in archived storage and burdensome to retrieve.

If defendants are willing to accept a compromise reaching the active files for the defined products, we will further compromise and produce the product analyses that are responsive.

joe

Joseph T. Lukens

10/3/2006

Message

Page 2 of 6

Hangley Aronchick Segal & Pudlin
One Logan Square, 27th Floor
Philadelphia, PA 19103
215-496-7032
215-568-0300 fax
jluken@hangley.com
www.hangley.com

-----Original Message-----

From: Demuth, Brad [mailto:Brad.Demuth@cw.com]
Sent: Tuesday, October 03, 2006 5:01 PM
To: Lukens, Joseph T.
Cc: sperwin@kennynachwalter.com; lravkind@kennynachwalter.com; Hendrickson, Matthew; Bickham, Timothy; Peterman, Chad J. (x2877); Reinhart, Tara
Subject: RE: Tricor Letter

Joe: We spoke about different standards for (i) documents created by or on behalf of the Direct Purchasers; and (ii) other documents in the possession, custody or control of the Direct Purchasers, but not created by them or on their behalf

Category 1 With respect to the first category of documents, it is my understanding that you agreed to produce any responsive documents created by or on behalf of the Direct Purchasers

Category 2 You stated that producing all responsive documents that were not created by or on behalf of the Direct Purchasers would be unduly burdensome. To address your concern of burden for these documents, as part of an overall agreement on what you would produce, we agreed that for the second category of documents, you will produce documents concerning fenofibrate and any one of the 9 products we identified. I understand that we are in agreement on this point, subject to reaching an overall agreement

The reference to _____ in my letter and email was not a limitation on the agreement that you would produce all responsive documents in Category 1. It was simply meant to make absolutely clear that we expect to receive all of the _____ produced by or on behalf of the Direct Purchasers. For example, we know from our deposition of Waldgreen that these documents were _____ and we want to be certain that we will receive these documents, whether or not they refer to fenofibrate

Please note that our agreement on limiting Category 2 was done in consideration of all of the Direct Purchasers agreeing to provide all responsive documents in Category 1. If you have a different position on Category 1, we cannot agree to any other limitation at this time but are happy to discuss further

Kind regards,
Brad

From: Lukens, Joseph T. [mailto:jtl@hangley.com]
Sent: Tuesday, October 03, 2006 3:15 PM
To: Demuth, Brad
Cc: sperwin@kennynachwalter.com; lravkind@kennynachwalter.com; Hendrickson, Matthew; Bickham, Timothy; Peterman, Chad J. (x2877); Reinhart, Tara
Subject: RE: Tricor Letter

Brad,

With respect to number 1, and particularly to the _____, your September 29th letter specifically discussed this request as a footnote to our agreement that "such documents would include those that compare, discuss, and/or mention fenofibrate (TriCor or any other

10/3/2006

Message

Page 3 of 6

fenofibrate product) in relation to, or in connection with, any non-fenofibrate lipid regulating product. Our compromise offer was in that context and was to produce all forms, or similar documents, that refer to fenofibrate

As worded in your email of October 3, the proposed compromise on the request is not limited to analyses that refer to fenofibrate products and any other product, but reaches analyses that do not mention fenofibrate products. I believe that is beyond the scope of what we discussed and what we were willing to agree to

As we had discussed, the definition of "lipid" products includes at least 47 different products. Note also that your letter of September 29 suggests that I indicated that this posed "an undue burden because of the vast number of other lipid regulating products that compete with TriCor." As I believe you will agree, I never agreed these products compete with TriCor, but discussed this issue in the context of Defendants' chosen definition of lipid regulating products. As we discussed, these 47 products also include generic versions of the listed products, which potentially implicates a much larger set of products - since, each generic typically could be offered by multiple companies. As such, the request is still very broad.

As stated above, Plaintiffs are willing to search for any forms (or similar documents) that mention any fenofibrate products and any of the defined lipid regulating products.

As an alternative with respect to the forms, Plaintiffs will search for any forms (or similar documents) for the fenofibrate products and for the 9 lipid regulating products referenced in your September 29 letter (regardless of whether those documents mention fenofibrate).

Please let me know if either the original compromise offer or this alternative compromise is acceptable.

With respect to number 2, I believe we are in agreement.

joe

Joseph T. Lukens
Hangley Aronchick Segal & Pudlin
One Logan Square, 27th Floor
Philadelphia, PA 19103
215-496-7032
215-568-0300 fax
jlukens@hangley.com
www.hangley.com

-----Original Message-----

From: Demuth, Brad [mailto:Brad.Demuth@cwt.com]

Sent: Tuesday, October 03, 2006 12:21 PM

To: Lukens, Joseph T

Cc: sperwin@kennynachwalter.com; travkind@kennynachwalter.com; Hendrickson, Matthew; Bickham, Timothy; Peterman, Chad J (k2877); Reinhart, Tara

Subject: RE: Tricor Letter

Joe: I believe we may have reached an agreement that resolves our dispute, but to be clear:

10/3/2006

Message

Page 4 of 6

(1) Each Direct Purchaser Plaintiff is agreeing to produce any analyses conducted by or on the behalf of a Direct Purchaser Plaintiff that are responsive to Defendants' requests. To avoid all doubt, this would include -- but is not limited to -- production of all the for Vytorin, Crestor, Zetia, and other lipid products regardless of whether these documents mention or refer to TriCor (or any other fenofibrate product, or fenofibrate generally)

(2) Each Direct Purchaser Plaintiff is agreeing to produce documents in its custody or control which were prepared by someone other than its agents or employees that compare, discuss and/or mention TriCor (or any other fenofibrate product, or fenofibrate generally) in connection with or in relation to any of the 9 products I identified in my September 29 letter

The above constitutes the compromise I described in my September 29 letter. I understand from your email below that each Direct Purchaser Plaintiff has agreed to the terms of that compromise. Please confirm that my understanding is accurate, so that I can communicate to the Court that we have resolved our dispute.

Kind regards,
Brad

From: Lukens, Joseph T. [mailto:jt1@hangley.com]
Sent: Monday, October 02, 2006 3:30 PM
To: Demuth, Brad
Cc: sperwin@kennynachwalter.com; lravkind@kennynachwalter.com
Subject: Re: Tricor Letter

Brad, I am out of town today, so pardon the email response.

While there are some things in your letter that are not consistent with our conversation (mostly, when speaking about how files are maintained, I was only speaking generally about CVS -- I have no idea about how the Walgreen plaintiffs keep their files), we agree to search for the materials that compare, discuss, and/or mention fenofibrate in connection with the 9 listed products requested in the third set of requests in the product files and any analyses our employees or their consultants did.

This will be labor intensive, but if we reach agreement, we will get the request to the clients as soon as possible.

Let me know if this will resolve our dispute.

Joe

----- Original Message -----

From: Demuth, Brad <Brad.Demuth@cw.com>
To: Lukens, Joseph T.; Chad Peterman <cjpeterman@phwt.com>; Hendrickson, Matthew
Matthew.Hendrickson@cw.com>
Cc: McGeever, Elizabeth M. <EMMcGeever@Prickett.com>; William F. Cavanaugh
<wfcavanaugh@phwt.com>; Abbott, Graham <tricolor@mnat.com>; Adam M. Steinfeld
<asteinfeld@garwingerstein.com>; Asim Bhansali <abhansali@kvn.com>; Bruce E. Gerstein
<bgerstein@garwingerstein.com>; Daniel Berger <daberger@bm.net>; David P. Germaine
<dgermaine@daarvaneck.com>; Direct Plaintiffs/Goddess <jgoddess@rmggglaw.com>; McGeever, Elizabeth
M. <EMMcGeever@Prickett.com>; Eric L. Cramer <ecramer@bm.net>; Fournier/Gaza <tricolor@rlt.com>;
Impax/Matterer <mmatterer@morrisjames.com>; Indirect Plaintiffs/Tikellis <tricolor@chimicles.com>; Jeffrey
Swann <jjs5@rawlingsandassociates.com>; John C. Vetter <jvetter@kenyon.com>; Joseph Vanek
<jvanek@daarvaneck.com>; Ken Zylstra <kzylstra@sbelasslaw.com>; Lauren C. Ravkind
<lravkind@kennynachwalter.com>; Linda P. Nussbaum <lnussbaum@cmht.com>; Mark Sandman
<mmst@rawlingsandassociates.com>; Michael I. Silverman <mike@silverman-mcdonald-psemail.com>;
Pacificare Parshull <jonp@msllaw.com>; Patrick Francis Morris <pmorris@morrisandmorrislaw.com>; Peter
Kohn <pkohn@bm.net>; Steig D. Olson <solson@cmht.com>; Teva Pharm/Ingersoll <tricolor@yest.com>;

10/3/2006

Message

Page 5 of 6

Walgreen/Perwin <spervin@kennynachwalter.com>; William Christopher Carmody
 <bcarmody@susmangodfrey.com>; Connolly, Stacy M. <AMConnolly@Prickett.com>; Baletsa, S. Jason P
 <JBaletsa@goodwinprocter.com>; Shadowen, Steve: travkind@kennynachwalter.com
 Sent: Fri Sep 29 15:28:22 2006
 Subject: RE: Tricor Letter

Counsel: Attached please find a letter addressed to Mr. Lukens

Enjoy your weekend

Kind regards
 Brad

From: Lukens, Joseph L [mailto:jl@hangley.com]
 Sent: Friday, September 22, 2006 4:15 PM
 To: Demuth, Brad; Chad Peterman; Hendrickson, Matthew
 Cc: McGeever, Elizabeth M.; William F. Cavanaugh; Abbott/Graham; Adam M. Steinfeld; Asim Bhansali;
 Bruce F. Gerstein; Daniel Berger; David P. Germaine; Direct Plaintiffs/Goddess; McGeever, Elizabeth M.;
 Eric L. Cramer; Fournier/Gaza; Impax/Matterer; Indirect Plaintiffs/Tikellis; Jeffrey Swann; John C. Vetter;
 Joseph Vanek; Ken Zylstra; Lauren C. Ravkind; Linda P. Nussbaum; Mark Sandman; Michael I. Silverman;
 Pacificare Parshall; Patrick Francis Morris; Peter Kohn; Steig D. Olson; Teva Pharm/Ingersoll;
 Walgreen/Perwin; William Christopher Carmody; Connolly, Stacy M.; Baletsa, S. Jason P.; Shadowen, Steve;
 travkind@kennynachwalter.com
 Subject: Tricor Letter

Counsel:

Attached is a letter to Messrs. DeMuth and Peterman. And, with regard to the prospective hearing date of Oct
 6 referenced in Anne Gaza's email of last night, that date is fine with CVS and Rite Aid.

Have a nice weekend

joe

Joseph L. Lukens
 Hangley Aronchick Segal & Pudin
 One Logan Square, 27th Floor
 Philadelphia, PA 19103
 215-496-7032
 215-568-0300 fax
 jlukens@hangley.com
 www.hangley.com <http://www.hangley.com>

----- IRS Circular 230 Legend: Any advice contained herein was not intended or written
 to be used, and cannot be used, for the purpose of avoiding U.S. federal, state, or local tax penalties. Unless
 otherwise specifically indicated above, you should assume that any statement in this email relating to any U.S.
 federal, state, or local tax matter was written in connection with the promotion or marketing by other parties of
 the transaction(s) or matter(s) addressed in this email. Each taxpayer should seek advice based on the
 taxpayer's particular circumstances from an independent tax advisor. ----- NOTE: The
 information in this email is confidential and may be legally privileged. If you are not the intended recipient,
 you must not read, use or disseminate the information; please advise the sender immediately by reply email
 and delete this message and any attachments without retaining a copy. Although this email and any
 attachments are believed to be free of any virus or other defect that may affect any computer system into

10/3/2006

Message

Page 6 of 6

which it is received and opened it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by Cadwalader Wickersham & Taft LLP for any loss or damage arising in any way from its use

10/3/2006

**EXHIBITS 20-21
REDACTED**